{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    11,
    12,
    13,
    19,
    28,
    34,
    37,
    39,
    40,
    41,
    42,
    44,
    46,
    52,
    54
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Safety and Management Guidelines",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.2.2.2",
        "sectionTitle": "Safety of Atezolizumab Monotherapy",
        "description": "Reference to immune-mediated events associated with atezolizumab"
      },
      {
        "id": "ref_2",
        "name": "Potential Risks",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1.2",
        "sectionTitle": "Potential Risks for Atezolizumab",
        "description": "Reference to hemophagocytic lymphohistiocytosis and macrophage activation syndrome"
      },
      {
        "id": "ref_3",
        "name": "Adverse Event Management",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1.4",
        "sectionTitle": "Management Guidelines",
        "description": "Reference to updated risk management guidelines"
      },
      {
        "id": "ref_4",
        "name": "Dose Modifications",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1.5.3.2",
        "sectionTitle": "Paclitaxel Dose Modifications",
        "description": "Reference for paclitaxel dose modifications due to toxicity"
      },
      {
        "id": "ref_5",
        "name": "Special Interest Events",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2.3",
        "sectionTitle": "Adverse Events of Special Interest",
        "description": "Reference regarding removal of systemic immune activation"
      },
      {
        "id": "ref_6",
        "name": "Schedule of Activities",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 1",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference to the study schedule and removal of PK/ADA samples at Follow-Up"
      },
      {
        "id": "ref_7",
        "name": "Management Guidelines Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 11",
        "sectionTitle": "Risks Associated with Atezolizumab",
        "description": "Reference to detailed management guidelines for immune-mediated events"
      },
      {
        "id": "ref_8",
        "name": "Study Schema",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Figure 1",
        "sectionTitle": "Study Schema",
        "description": "Internal link to the visual study design schema"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Immune-related has been changed to immune-mediated when describing events associated with atezolizumab to align with Investigator's Brochure v15.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Rationale",
        "pageNumber": 3
      },
      {
        "id": "annot_2",
        "text": "Systemic immune activation has been replaced by hemophagocytic lymphohistiocytosis and macrophage activation syndrome per French ANSM request.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Rationale",
        "pageNumber": 3
      },
      {
        "id": "annot_3",
        "text": "Serum pharmacokinetic/anti-drug antibody samples removed at Follow-Up as assessment was discontinued as of Version 3.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Rationale",
        "pageNumber": 3
      },
      {
        "id": "annot_4",
        "text": "Recommended that the dose of dexamethasone is minimised to the extent clinically feasible to avoid ablating early immune activity.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Paclitaxel (Background Chemotherapy)",
        "pageNumber": 29
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-02-14",
        "description": "Initial Version",
        "amendmentNumber": "N/A"
      },
      {
        "id": "ver_2",
        "versionNumber": "2.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-05-12",
        "description": "Amended Version",
        "amendmentNumber": "Amendment 1"
      },
      {
        "id": "ver_3",
        "versionNumber": "3.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-12-05",
        "description": "Amended Version",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_4",
        "versionNumber": "4.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2018-12-17",
        "description": "Amended Version",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_5",
        "versionNumber": "5.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-05-23",
        "description": "Amended Version",
        "amendmentNumber": "Amendment 4"
      },
      {
        "id": "ver_6",
        "versionNumber": "6.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-02-11",
        "description": "Protocol Amendment 6.0: Rationale includes alignment with IB v15 and French ANSM requests.",
        "amendmentNumber": "Amendment 5"
      }
    ],
    "summary": {
      "referenceCount": 8,
      "annotationCount": 4,
      "versionCount": 6
    }
  }
}